Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

NCT04954339 is registered in ClinicalTrials.gov with Tae Won Kim as lead sponsor.

NCT NCT04954339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04954339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
Lead sponsor
Tae Won Kim
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2021
Completion date
May 26, 2026
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma